OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches … Continue reading “Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences”
• Level 1 evidence from the MAF Test® analyses of the NSABP-B34 … Continue reading “Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Announces Interim Results for the Six Months ended 30 June 2021”
Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US … Continue reading “Third ADC with Synaffix’s Technology Enters Clinical Development”
The project will support more than 4,300 refugees and other conflict-affected populations … Continue reading “The Novo Nordisk Foundation is awarding a grant of DKK 20 million to support an innovative new project aiming to increase sustainable livelihoods for Syrian refugees in Jordan.”
Polθ inhibitor, ART4215, is the first selective, orally bioavailable, small molecule inhibitor of … Continue reading “Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215”
Three abstracts accepted at EBJIS Annual Meeting demonstrating efficacy of STIMULAN beads … Continue reading “Biocomposites to host a symposium and present new STIMULAN® data at the European Bone and Joint Infection Society Annual Meeting”
Brighton, United Kingdom – 27 September 2021 – Destiny Pharma (AIM: DEST), a … Continue reading “Destiny Pharma plc: Expansion of clinical pipeline”
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing … Continue reading “Futura Medical Announces Collaboration with Labatec Pharma to Commercialise MED3000 in the Gulf and Middle East Region”
Hangzhou, China and Diepenbeek, Belgium, (August 18, 2021): Worg Pharmaceuticals (Hangzhou) Co., Ltd … Continue reading “Worg Pharma to Acquire Apitope”
September 22nd 2021: EXACT Therapeutics AS (‘EXACT-Tx’) announces its interim results for … Continue reading “EXACT Therapeutics AS announces interim results for first half 2021”
BioInnovation Institute (BII), an international commercial foundation with a non-profit objective of … Continue reading “BII welcomes four new companies to the Creation House program”
The Novo Nordisk Foundation is awarding the Novo Nordisk Prize to pioneering … Continue reading “Four scientists receive the Novo Nordisk Prize for their combined contributions to COVID-19 mRNA vaccine”
The Novo Nordisk Foundation has awarded €84.7 million for establishing the world’s … Continue reading “Novo Nordisk Fonden: New research center will find solutions to reduce CO2 in the atmosphere and convert it into valuable raw materials”
We are delighted to announce that China Medical System is now part … Continue reading “China Medical System joins BaseLaunch as latest partner”
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies … Continue reading “eTheRNA immunotherapies conference attendance from September to October 2021”
– Agreement with Advanced Accelerator Applications, a Novartis company enables development of easy-to-use … Continue reading “Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals”
Copenhagen, Denmark and Boston, US – 21 September 2021 Hemab ApS (“Hemab”), … Continue reading “Hemab Appoints Mads Behrndt as Chief Financial Officer”
17 September 2021 Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a … Continue reading “Futura Medical Notice of Interim Results”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
